Pharmacokinetics analysis of novel candidate drugs against hepatic B virus

• In: Poster Presentation
• At: Stockholm (Sweden) (2017)
• Type: Poster
• Poster code: P-A-076-Monday
• By: HASHIMOTO, Mai (Sojo University, Faculty of Pharmaceutical Sciences, Kumamoto, Japan)
• Co-author(s): Mai Hashimoto: Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan
  Kazuaki Taguchi: Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan
  Takako Ishiguro: Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan
  Keishi Yamasaki: Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan;DDS Research Institutes, Sojo University, Kumamoto, Japan
  Satoru Kohgo: Research Institute & Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
  Hiroaki Mitsuya: Research Institute & Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan;National Cancer Institute, National Institutes of Health, Bethesda, MD, United States;Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
  Masaki Otagiri: Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan;DDS Research Institutes, Sojo University, Kumamoto, Japan
  
• Abstract:

  Backgrounds

  Although a few drug against hepatitis B virus (HBV) are approved and used in clinics all over the world, there are some limitations to completely treat HBV because of the appearance of drug-resistance HBV. To overcome this issue, it is desirable to develop novel drugs against drug-resistance HBV. Our group have developed..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login